CN105031597A - Traditional Chinese medicine drug used for treating infertility and habitual abortion - Google Patents
Traditional Chinese medicine drug used for treating infertility and habitual abortion Download PDFInfo
- Publication number
- CN105031597A CN105031597A CN201510543496.1A CN201510543496A CN105031597A CN 105031597 A CN105031597 A CN 105031597A CN 201510543496 A CN201510543496 A CN 201510543496A CN 105031597 A CN105031597 A CN 105031597A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- herba
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine drug used for treating infertility and habitual abortion. The drug comprises, by weight, 12-15 parts of red ginseng, 18-20 parts of radix codonopsis, 12-18 parts of atractylodes macrocephala koidz, 12-15 parts of poria, 12-15 parts of pinellia ternate, 15-18 parts of astragalus, 9-15 parts of amomum, 12-18 parts of eucommia, 15-20 parts of herba taxilli, 12-15 parts of semen cuscutae, 12-15 parts of dipsacus roots, 12-18 parts of jujubes, 6-9 parts of licorice roots, 6-10 parts of fresh ginger, 10-15 parts of cornus pulp, 12-15 parts of cistanche salsa, 15-18 parts of Chinese yam, 12-15 parts of morinda officinalis, 12-15 parts of hawthorn fruits, 12-15 parts of Chinese wolfberries, 12-15 parts of angelica sinensis, 12-18 parts of epimedium, 12-15 parts of rhizoma curculiginis, 12-15 parts of polygonatum kingianum, 12-15 parts of pericarpium citri reticulatae and 9-12 parts of ganoderma lucidum. According to the traditional Chinese medicine drug, natural traditional Chinese herb raw materials are adopted, medicinal resources are wide, cost is low, preparation is easy, toxic and side effects are few, and the treatment effect is obvious.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese drugs agentia for the treatment of sterility and infertility and habitual abortion.
Background technology
Habitual abortion is department of obstetrics and gynecology commonly encountered diseases.Refer to that spontaneous abortion recurs 3 times or more, each time occurred, can in same gestation month, also free length difference person.Its clinical manifestation with generally miscarry identical, according to the time occurred, early abortion and late abortion two class can be divided into, before early abortion occurs in pregnant 12 weeks, relevant with the factor such as heredity, parent endocrine disturbance and immunity, occurring in gestation is late abortion after 12 weeks, with uterine malformation, cervical dysplasias is bad, blood group incompatibility, and mother to suffer from the disease etc. relevant.Because the habitual abortion cause of disease is comparatively complicated, it is more difficult to treat.
In the traditional Chinese medical science, habitual abortion has another name called habitual abortion, vaginal bleeding during pregnancy, mostly loses because spleen kidney is two and causes a disease, has that lumbago, lower abdomen burdensome are tired bitterly, deep and weak pulse and unable a, pale tongue or have the symptom such as indentation, thin fur.Along with socio-economic development, some women being in growing stage because life stress is large, it is irregular to live, diet not the reason such as science, disorder of emotion very easily cause overstrain internal injury, cause spleen kidney two empty.Kidney qi loss, can not consolidate tire; Deficiency-weakness of spleen-QI, can not carry tire, thus finally cause habitual abortion.At present, treat these much more sick progestogen such as injection Progesterone that adopt and prevent miscarriage, this therapeutic modality not only costly, cure rate is low, and cause great negative interaction to anemia of pregnant woman's health.
Summary of the invention
The object of this invention is to provide a kind of Chinese drugs agentia for the treatment of sterility and infertility and habitual abortion.
In order to realize object of the present invention, the invention provides a kind of Chinese drugs agentia for the treatment of sterility and infertility and habitual abortion, it comprises material Radix Ginseng Rubra 12-15 part of following weight portion, Radix Codonopsis 18-20 part, Rhizoma Atractylodis Macrocephalae 12-18 part, Poria 12-15 part, Rhizoma Pinelliae 12-15 part, Radix Astragali 15-18 part, Fructus Amomi 9-15 part, Cortex Eucommiae 12-18 part, Herba Taxilli 15-20 part, Semen Cuscutae 12-15 part, Radix Dipsaci 12-15 part, Fructus Jujubae 12-18 part, Radix Glycyrrhizae 6-9 part, Rhizoma Zingiberis Recens 6-10 part, Fructus Corni 10-15 part, Herba Cistanches 12-15 part, Rhizoma Dioscoreae 15-18 part, Radix Morindae Officinalis 12-15 part, Fructus Crataegi 12-15 part, Fructus Lycii 12-15 part, Radix Angelicae Sinensis 12-15 part, Herba Epimedii 12-18 part, Rhizoma Curculiginis 12-15 part, Rhizoma Polygonati 12-15 part, Pericarpium Citri Reticulatae 12-15 part and Ganoderma 9-12 part.
Preferably, the Chinese drugs agentia for the treatment of sterility and infertility of the present invention and habitual abortion comprises the material of following weight portion: Radix Ginseng Rubra 13 parts, Radix Codonopsis 19 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Poria 13 parts, the Rhizoma Pinelliae 13 parts, the Radix Astragali 16 parts, Fructus Amomi 10 parts, the Cortex Eucommiae 13 parts, Herba Taxilli 18 parts, Semen Cuscutae 13 parts, Radix Dipsaci 13 parts, 13 parts, Fructus Jujubae, 8 parts, Radix Glycyrrhizae, 8 parts, Rhizoma Zingiberis Recens, Fructus Corni 12 parts, Herba Cistanches 13 parts, Rhizoma Dioscoreae 16 parts, Radix Morindae Officinalis 13 parts, Fructus Crataegi 13 parts, Fructus Lycii 13 parts, Radix Angelicae Sinensis 13 parts, Herba Epimedii 15 parts, Rhizoma Curculiginis 13 parts, Rhizoma Polygonati 13 parts, Pericarpium Citri Reticulatae 13 parts and Ganoderma 10 parts.
More preferably, the Chinese drugs agentia for the treatment of sterility and infertility of the present invention and habitual abortion also comprises the material of following weight portion: Herba Blumeae clarkei 15 parts, Flos Gomphrenae 13 parts, Impatiens leptocaulon Hook.f. 12 parts, Caulis et Folium Crotalariae Assamicae 10 parts, Cortex Populi Tomentosae 12 parts, Semen Ciceris Arietini 13 parts, Herba Briggsiae Chienii 11 parts, Fructus Styracis obassiae 10 parts, Herba Lysimachiae Insignis 12 parts, Oreas martiana (Hopp. Et Hornsch.) Brid. 10 parts, Folium seu Radix Rubi Ichangensis 11 parts, Herba Leontopodii Leontopodioidis 10 parts and Radix Schizonepetae 10 parts.
Most preferably, described Chinese drugs agentia can be tablet, dispersible tablet, capsule, unguentum or decoction.
The present invention also provides the purposes of compositions in the Chinese medicine preparing treatment sterility and infertility and habitual abortion, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 12-15 part, Radix Codonopsis 18-20 part, Rhizoma Atractylodis Macrocephalae 12-18 part, Poria 12-15 part, Rhizoma Pinelliae 12-15 part, Radix Astragali 15-18 part, Fructus Amomi 9-15 part, Cortex Eucommiae 12-18 part, Herba Taxilli 15-20 part, Semen Cuscutae 12-15 part, Radix Dipsaci 12-15 part, Fructus Jujubae 12-18 part, Radix Glycyrrhizae 6-9 part, Rhizoma Zingiberis Recens 6-10 part, Fructus Corni 10-15 part, Herba Cistanches 12-15 part, Rhizoma Dioscoreae 15-18 part, Radix Morindae Officinalis 12-15 part, Fructus Crataegi 12-15 part, Fructus Lycii 12-15 part, Radix Angelicae Sinensis 12-15 part, Herba Epimedii 12-18 part, Rhizoma Curculiginis 12-15 part, Rhizoma Polygonati 12-15 part, Pericarpium Citri Reticulatae 12-15 part and Ganoderma 9-12 part.
Preferably, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 13 parts, Radix Codonopsis 19 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Poria 13 parts, the Rhizoma Pinelliae 13 parts, the Radix Astragali 16 parts, Fructus Amomi 10 parts, the Cortex Eucommiae 13 parts, Herba Taxilli 18 parts, Semen Cuscutae 13 parts, Radix Dipsaci 13 parts, 13 parts, Fructus Jujubae, 8 parts, Radix Glycyrrhizae, 8 parts, Rhizoma Zingiberis Recens, Fructus Corni 12 parts, Herba Cistanches 13 parts, Rhizoma Dioscoreae 16 parts, Radix Morindae Officinalis 13 parts, Fructus Crataegi 13 parts, Fructus Lycii 13 parts, Radix Angelicae Sinensis 13 parts, Herba Epimedii 15 parts, Rhizoma Curculiginis 13 parts, Rhizoma Polygonati 13 parts, Pericarpium Citri Reticulatae 13 parts and Ganoderma 10 parts.
More preferably, described compositions also comprises the material of following weight portion: Herba Blumeae clarkei 15 parts, Flos Gomphrenae 13 parts, Impatiens leptocaulon Hook.f. 12 parts, Caulis et Folium Crotalariae Assamicae 10 parts, Cortex Populi Tomentosae 12 parts, Semen Ciceris Arietini 13 parts, Herba Briggsiae Chienii 11 parts, Fructus Styracis obassiae 10 parts, Herba Lysimachiae Insignis 12 parts, Oreas martiana (Hopp. Et Hornsch.) Brid. 10 parts, Folium seu Radix Rubi Ichangensis 11 parts, Herba Leontopodii Leontopodioidis 10 parts and Radix Schizonepetae 10 parts.
Most preferably, described Chinese medicine can be tablet, dispersible tablet, capsule, unguentum or decoction.
Chinese drugs agentia of the present invention interacts, and synergism is evident in efficacy, highly widelys popularize.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment 1 decoction of the present invention
Take Radix Ginseng Rubra 13 grams, Radix Codonopsis 19 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Poria 13 grams, the Rhizoma Pinelliae 13 grams, the Radix Astragali 16 grams, Fructus Amomi 10 grams, the Cortex Eucommiae 13 grams, Herba Taxilli 18 grams, Semen Cuscutae 13 grams, Radix Dipsaci 13 grams, 13 grams, Fructus Jujubae, 8 grams, Radix Glycyrrhizae, 8 grams, Rhizoma Zingiberis Recens, Fructus Corni 12 grams, Herba Cistanches 13 grams, Rhizoma Dioscoreae 16 grams, Radix Morindae Officinalis 13 grams, Fructus Crataegi 13 grams, Fructus Lycii 13 grams, Radix Angelicae Sinensis 13 grams, Herba Epimedii 15 grams, Rhizoma Curculiginis 13 grams, Rhizoma Polygonati 13 grams, Pericarpium Citri Reticulatae 13 grams and Ganoderma 10 grams, pulverize, cross 60 mesh sieves, add 6000 ml waters, heating 3 hours under the condition of backflow, filter, filtrate is cooled to room temperature, obtain.
Embodiment 2 decoction of the present invention
Take Radix Ginseng Rubra 13 grams, Radix Codonopsis 19 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Poria 13 grams, the Rhizoma Pinelliae 13 grams, the Radix Astragali 16 grams, Fructus Amomi 10 grams, the Cortex Eucommiae 13 grams, Herba Taxilli 18 grams, Semen Cuscutae 13 grams, Radix Dipsaci 13 grams, 13 grams, Fructus Jujubae, 8 grams, Radix Glycyrrhizae, 8 grams, Rhizoma Zingiberis Recens, Fructus Corni 12 grams, Herba Cistanches 13 grams, Rhizoma Dioscoreae 16 grams, Radix Morindae Officinalis 13 grams, Fructus Crataegi 13 grams, Fructus Lycii 13 grams, Radix Angelicae Sinensis 13 grams, Herba Epimedii 15 grams, Rhizoma Curculiginis 13 grams, Rhizoma Polygonati 13 grams, Pericarpium Citri Reticulatae 13 grams, Ganoderma 10 grams, Herba Blumeae clarkei 15 grams, Flos Gomphrenae 13 grams, Impatiens leptocaulon Hook.f. 12 grams, Caulis et Folium Crotalariae Assamicae 10 grams, Cortex Populi Tomentosae 12 grams, Semen Ciceris Arietini 13 grams, Herba Briggsiae Chienii 11 grams, Fructus Styracis obassiae 10 grams, Herba Lysimachiae Insignis 12 grams, Oreas martiana (Hopp. Et Hornsch.) Brid. 10 grams, Folium seu Radix Rubi Ichangensis 11 grams, Herba Leontopodii Leontopodioidis 10 grams and Radix Schizonepetae 10 grams, pulverize, cross 60 mesh sieves, add 6000 ml waters, heating 3 hours under the condition of backflow, filter, filtrate is cooled to room temperature, obtain.
Experimental example
Diagnostic criteria
Western medicine diagnose standard
Diagnosis of Endometriosis standard
Formulate according to " the Clinics and Practices specification of endometriosis " (Chinese journal of obstetrics and gynecology, the 42nd volume the 9th phase in 2007) and " Chinese obstetrics and gynecology " (Cao Zeyi edits, 2004 the 2nd edition).
Clinical diagnosis:
1. progressive dysmenorrhea;
2. chronic pelvic pain;
3. sexual anhedonia;
4. infertile;
5. posterior fornix, uterus human bones ligament or isthmus uteri touch painful tubercles;
6. side, uterus or bilateral can touch cystic or capsule Space-occupying lesions, can become enclosed mass with surrounding tissue adhesion;
7. CA
125increase;
8. B ultrasonic prompting endometriosis.
All have one of one of 1. above ~ one of 4. item and 5.-6. item and 7.-8. item person, namely can be used as clinical diagnosis.
Laparoscopy is diagnosed:
1. uterus rectal sinuses, posterior peritoneum are shown in multiple purple blue point, and companion's peritoneal fluid increases (normal for courageous and upright);
2. human bones ligament in uterus increases thick, canescence tuberosity, and with loose adhesion, fallopian tube majority is unobstructed;
3. ovary peplos thickens, air spots, adhesion, and Common surface has brown remote hemorrhage speckle, and ovary punctures to obtain the old blood of chocolate-like;
4. ovary has adhesion, and fallopian tube is mostly unobstructed.
Pathological diagnosis standard: have following evidence in section
1. endometrial gland;
2. endometrial stroma;
3. internal hemorrhage evidence in a organized way, show cell, iron content haemachrome, local connective tissue hypertrophy can be made a definite diagnosis.
Infertility diagnosis standard
Write " Infertile couples standard checks and diagnosis handbook " with reference to national higher institutions of Chinese medicine programming textbook " Gynecology of Chinese Medicine " (the 7th edition, China Traditional Chinese Medicine Publishing House 2002 publish), World Health Organization (WHO), " clinic diagnosis guide (obstetrics and gynecology fascicle) " (People's Health Publisher publishes for 2007) draft.All woman do not practise contraception after marriage, have normal sexuality, live together 1 year, and the person of not becoming pregnant, be primary infertility.Or once had gestation, then do not practise contraception, the continuous 1 year person that do not become pregnant again, is secondary infertility again.
Standards of Chinese Medical Syndrome Differentiation
Formulate with reference to " new Chinese medicine guideline of clinical investigations " (version in 2002) " guideline of clinical investigations of new Chinese medicine treatment infertility ", " the clinical guidance principle of new Chinese medicine treatment endometriosis of pelvis ", national higher institutions of Chinese medicine programming textbook " Gynecology of Chinese Medicine " (the 7th edition, China Traditional Chinese Medicine Publishing House publishes for 2002) and seminar's clinical experience for many years.
Qi stagnation and blood stasis type is infertile:
Primary symptom: 1. wed infertile for a long time; 2. blockage of menstruation, accompanies clot; 3. uncomfortable in chestly not relax.
Secondary disease: 1. premenstrual inferior belly gas pain; 2. abdominal pain during menstruation; 3. premenstrual distending pain of the breast; 4. rectal tenesmus; 5. dyspareunia.
Tongue arteries and veins: purplish tongue is dark, and limit point has addiction point, white and thin fur, stringy pulse.
Possess above primary symptom three, secondary disease 2 or more, in conjunction with tongue arteries and veins, can distinguish as assertive evidence.
Inclusive criteria
1 meets endometriosis is correlated with infertility diagnosis standard;
2 meet Syndrome Differentiation of Traditional Chinese Medicine standard;
3 row hydrotubation or Salpingographies, at least one oviductus lateralis is unobstructed or block lighter;
Do not use the medicine for the treatment of primary disease 4 preoperative March;
5 without severe primary diseases such as cardiovascular and cerebrovascular vessel, liver, kidney and hemopoietic systems, and be a cup too low medical history;
6 ages are in 22-40 year;
7 can stablize the person of following up a case by regular visits to.
Exclusion standard
1 is associated with hysteromyoma, adenomyosis, polycystic ovary syndrome, premature ovarian failure person;
2 have severe drug allergies person;
3 bridegroom's or husband's side factors are infertile.
Selector closes female patient 60 example of standard of stating, patient age 25-38 year, the mean age be (30 ± 2) year, be two groups by patient, be respectively treatment group 1 patient 30 example, treatment group 2 patient 30 is routine.Two groups of Genders, age, the course of disease, symptom there are no significant difference, have comparability (P > 0.05).
Treatment group 1 uses the decoction of preparation in embodiment 1 to treat.Menstrual cycle starts to take on the 1st, every day twice, oral 300 milliliters at every turn, within 1 hour after meal, takes, is used in conjunction 3 menstrual cycle.
Treatment group 2 uses the decoction of preparation in embodiment 2 to treat.Menstrual cycle starts to take on the 1st, every day twice, oral 300 milliliters at every turn, within 1 hour after meal, takes, is used in conjunction 3 menstrual cycle.
Curative effect judging standard
According to Zhang Yuzhen " Gynecology of Chinese Medicine " standard rating curative effect.Cure: symptom all disappears, pelvic lump and local sign disappear substantially, infertile patients gestation or fertility in 1 year after disappearing from symptom and sign; Effective: transference cure, pelvic lump reduces more than 1/2, and from transference cure, nothing recurrence in 1 year, can give birth to though local sign exists infertile patients; Effective: symptom significantly alleviates, pelvic lump reduces more than 1/3, and cardinal symptom disappears 1 year without recurrence; Invalid: cardinal symptom is unchanged or to worsen local patholoic change unchanged or have and increase the weight of trend.
Statistical method
Utilize SPSS13.0 software to process and analyze to experimental data, measurement data is with mean ± standard deviation
represent, adopt t inspection, enumeration data adopts x
2inspection, P < 0.05 represents that difference has statistical significance.
Therapeutic outcome
For treatment group 1, cure 9 examples, effective 10 examples, effective 5 examples, invalid 6 examples, total effective rate is 80%; For treatment group 2, cure 11 examples, effective 12 examples, effective 5 examples, invalid 2 examples, total effective rate is 93%.Two groups of total effective rate comparing differences have statistical significance (P < 0.05).The effect for the treatment of group 2 is better than the effect for the treatment of group 1.
Claims (8)
1. treat the Chinese drugs agentia of sterility and infertility and habitual abortion for one kind, it is characterized in that, it comprises the material of following weight portion: Radix Ginseng Rubra 12-15 part, Radix Codonopsis 18-20 part, Rhizoma Atractylodis Macrocephalae 12-18 part, Poria 12-15 part, Rhizoma Pinelliae 12-15 part, Radix Astragali 15-18 part, Fructus Amomi 9-15 part, Cortex Eucommiae 12-18 part, Herba Taxilli 15-20 part, Semen Cuscutae 12-15 part, Radix Dipsaci 12-15 part, Fructus Jujubae 12-18 part, Radix Glycyrrhizae 6-9 part, Rhizoma Zingiberis Recens 6-10 part, Fructus Corni 10-15 part, Herba Cistanches 12-15 part, Rhizoma Dioscoreae 15-18 part, Radix Morindae Officinalis 12-15 part, Fructus Crataegi 12-15 part, Fructus Lycii 12-15 part, Radix Angelicae Sinensis 12-15 part, Herba Epimedii 12-18 part, Rhizoma Curculiginis 12-15 part, Rhizoma Polygonati 12-15 part, Pericarpium Citri Reticulatae 12-15 part and Ganoderma 9-12 part.
2. the Chinese drugs agentia for the treatment of sterility and infertility according to claim 1 and habitual abortion, it is characterized in that, it comprises the material of following weight portion: Radix Ginseng Rubra 13 parts, Radix Codonopsis 19 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Poria 13 parts, the Rhizoma Pinelliae 13 parts, the Radix Astragali 16 parts, Fructus Amomi 10 parts, the Cortex Eucommiae 13 parts, Herba Taxilli 18 parts, Semen Cuscutae 13 parts, Radix Dipsaci 13 parts, 13 parts, Fructus Jujubae, 8 parts, Radix Glycyrrhizae, 8 parts, Rhizoma Zingiberis Recens, Fructus Corni 12 parts, Herba Cistanches 13 parts, Rhizoma Dioscoreae 16 parts, Radix Morindae Officinalis 13 parts, Fructus Crataegi 13 parts, Fructus Lycii 13 parts, Radix Angelicae Sinensis 13 parts, Herba Epimedii 15 parts, Rhizoma Curculiginis 13 parts, Rhizoma Polygonati 13 parts, Pericarpium Citri Reticulatae 13 parts and Ganoderma 10 parts.
3. the Chinese drugs agentia for the treatment of sterility and infertility according to claim 1 and 2 and habitual abortion, it is characterized in that, it also comprises the material of following weight portion: Herba Blumeae clarkei 15 parts, Flos Gomphrenae 13 parts, Impatiens leptocaulon Hook.f. 12 parts, Caulis et Folium Crotalariae Assamicae 10 parts, Cortex Populi Tomentosae 12 parts, Semen Ciceris Arietini 13 parts, Herba Briggsiae Chienii 11 parts, Fructus Styracis obassiae 10 parts, Herba Lysimachiae Insignis 12 parts, Oreas martiana (Hopp. Et Hornsch.) Brid. 10 parts, Folium seu Radix Rubi Ichangensis 11 parts, Herba Leontopodii Leontopodioidis 10 parts and Radix Schizonepetae 10 parts.
4. the Chinese drugs agentia for the treatment of sterility and infertility according to claim 3 and habitual abortion, is characterized in that, described Chinese drugs agentia can be tablet, dispersible tablet, capsule, unguentum or decoction.
5. the purposes of compositions in the Chinese medicine preparing treatment sterility and infertility and habitual abortion, it is characterized in that, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 12-15 part, Radix Codonopsis 18-20 part, Rhizoma Atractylodis Macrocephalae 12-18 part, Poria 12-15 part, Rhizoma Pinelliae 12-15 part, Radix Astragali 15-18 part, Fructus Amomi 9-15 part, Cortex Eucommiae 12-18 part, Herba Taxilli 15-20 part, Semen Cuscutae 12-15 part, Radix Dipsaci 12-15 part, Fructus Jujubae 12-18 part, Radix Glycyrrhizae 6-9 part, Rhizoma Zingiberis Recens 6-10 part, Fructus Corni 10-15 part, Herba Cistanches 12-15 part, Rhizoma Dioscoreae 15-18 part, Radix Morindae Officinalis 12-15 part, Fructus Crataegi 12-15 part, Fructus Lycii 12-15 part, Radix Angelicae Sinensis 12-15 part, Herba Epimedii 12-18 part, Rhizoma Curculiginis 12-15 part, Rhizoma Polygonati 12-15 part, Pericarpium Citri Reticulatae 12-15 part and Ganoderma 9-12 part.
6. purposes according to claim 5, it is characterized in that, described compositions comprises the material of following weight portion: Radix Ginseng Rubra 13 parts, Radix Codonopsis 19 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Poria 13 parts, the Rhizoma Pinelliae 13 parts, the Radix Astragali 16 parts, Fructus Amomi 10 parts, the Cortex Eucommiae 13 parts, Herba Taxilli 18 parts, Semen Cuscutae 13 parts, Radix Dipsaci 13 parts, 13 parts, Fructus Jujubae, 8 parts, Radix Glycyrrhizae, 8 parts, Rhizoma Zingiberis Recens, Fructus Corni 12 parts, Herba Cistanches 13 parts, Rhizoma Dioscoreae 16 parts, Radix Morindae Officinalis 13 parts, Fructus Crataegi 13 parts, Fructus Lycii 13 parts, Radix Angelicae Sinensis 13 parts, Herba Epimedii 15 parts, Rhizoma Curculiginis 13 parts, Rhizoma Polygonati 13 parts, Pericarpium Citri Reticulatae 13 parts and Ganoderma 10 parts.
7. the purposes according to claim 5 or 6, it is characterized in that, described compositions also comprises the material of following weight portion: Herba Blumeae clarkei 15 parts, Flos Gomphrenae 13 parts, Impatiens leptocaulon Hook.f. 12 parts, Caulis et Folium Crotalariae Assamicae 10 parts, Cortex Populi Tomentosae 12 parts, Semen Ciceris Arietini 13 parts, Herba Briggsiae Chienii 11 parts, Fructus Styracis obassiae 10 parts, Herba Lysimachiae Insignis 12 parts, Oreas martiana (Hopp. Et Hornsch.) Brid. 10 parts, Folium seu Radix Rubi Ichangensis 11 parts, Herba Leontopodii Leontopodioidis 10 parts and Radix Schizonepetae 10 parts.
8. purposes according to claim 7, is characterized in that, described Chinese medicine can be tablet, dispersible tablet, capsule, unguentum or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510543496.1A CN105031597A (en) | 2015-08-28 | 2015-08-28 | Traditional Chinese medicine drug used for treating infertility and habitual abortion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510543496.1A CN105031597A (en) | 2015-08-28 | 2015-08-28 | Traditional Chinese medicine drug used for treating infertility and habitual abortion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105031597A true CN105031597A (en) | 2015-11-11 |
Family
ID=54438956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510543496.1A Pending CN105031597A (en) | 2015-08-28 | 2015-08-28 | Traditional Chinese medicine drug used for treating infertility and habitual abortion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105031597A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111420014A (en) * | 2020-03-24 | 2020-07-17 | 张量才 | Medicine for treating infertility and habitual abortion and preparation method thereof |
| CN116139241A (en) * | 2021-11-19 | 2023-05-23 | 富顺大生堂医院 | Chinese medicinal composition for treating infertility and habitual abortion and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579752A (en) * | 2011-01-05 | 2012-07-18 | 张影 | Preparation method of kidney-tonifying and fetus-securing capsule for treating habitual abortion |
-
2015
- 2015-08-28 CN CN201510543496.1A patent/CN105031597A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579752A (en) * | 2011-01-05 | 2012-07-18 | 张影 | Preparation method of kidney-tonifying and fetus-securing capsule for treating habitual abortion |
Non-Patent Citations (1)
| Title |
|---|
| 国家中医药管理局人事教育司: "《农村基层优秀中医临床经验选编》", 31 May 2007 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111420014A (en) * | 2020-03-24 | 2020-07-17 | 张量才 | Medicine for treating infertility and habitual abortion and preparation method thereof |
| CN116139241A (en) * | 2021-11-19 | 2023-05-23 | 富顺大生堂医院 | Chinese medicinal composition for treating infertility and habitual abortion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101966313A (en) | Chinese medicinal composition for treating female infertility and preparation method thereof | |
| CN101342353B (en) | Traditional Chinese medicine preparation for treating barrenness and preparation method thereof | |
| CN103585378B (en) | A Chinese medicinal composition for treating female infertility, and its preparation method | |
| CN105031559B (en) | It is a kind of to treat the Chinese medicine for causing infertility by Stein-Leventhal syndrome | |
| CN104857478A (en) | Medical composition for treating hysteromyoma and preparation method of medical composition | |
| CN105412787A (en) | Medicine for treating postpartum irregular menstruation | |
| CN113855771B (en) | A Chinese medicinal composition for treating ovarian reserve function decline disease | |
| CN102319340A (en) | Traditional Chinese medicine composition for treating immune infertility | |
| CN102133376A (en) | Formula of Chinese medicinal herb for conditioning myoma of uterus | |
| CN103393989A (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN103349766A (en) | Pharmaceutical composition for endless postpartum lochia | |
| CN105031597A (en) | Traditional Chinese medicine drug used for treating infertility and habitual abortion | |
| CN103071018B (en) | Traditional Chinese medicine preparation for treating early habitual abortion | |
| CN103263650B (en) | Chinese medicament for conditioning female menstruation | |
| CN101590157B (en) | Chinese medicinal preparation for treating embryo diapause | |
| CN104873706A (en) | Traditional Chinese medicine composition for treating uterine cold infertility | |
| CN103751480A (en) | Traditional Chinese medicine for treating habitual abortion | |
| CN109966407B (en) | Vitality-cultivating and liver-nourishing pill | |
| CN103110798B (en) | Chinese medicinal formula for treating menstrual disorder type infertility and preparation method thereof | |
| CN113398223A (en) | Traditional Chinese medicine composition, powder and pill for treating infertility and preparation method and application thereof | |
| CN105944020A (en) | Traditional Chinese medicine for treating ovarian function decrease | |
| CN111420014A (en) | Medicine for treating infertility and habitual abortion and preparation method thereof | |
| CN103071017A (en) | Traditional Chinese medicine composition for treating infantile uterus and preparation method of same | |
| CN105056139A (en) | Chinese herbal preparation for treating female infertility | |
| CN103110722B (en) | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
| RJ01 | Rejection of invention patent application after publication |